Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
9.09
-0.24 (-2.57%)
At close: Feb 21, 2025, 4:00 PM
9.01
-0.08 (-0.88%)
After-hours: Feb 21, 2025, 7:58 PM EST
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
50
Market Cap
191.22M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 864.00K | - | - |
| Mar 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
CYBN News
- 11 days ago - Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Business Wire
- 5 weeks ago - Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
- 5 weeks ago - Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - Business Wire
- 6 weeks ago - Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Business Wire
- 2 months ago - Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results - Business Wire
- 2 months ago - Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Business Wire
- 3 months ago - Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire
- 3 months ago - Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - Business Wire